ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Beclomethasone

Also written as “Beclomethasone dipropionate”, “Beclometasone/Formoterol/Glycopyrrolate” and “beclomethasone”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Graft vs Host Disease, led by 7 companies.

Drug pageBeclomethasone: every studyMany companies study it; this page follows only the 44 they lead. All 85 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 28, 202044 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceuticiits history only220 open or runningphase 4since Oct 28, 2020Sep 29, 2006none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Oct 28, 2003Oct 28, 2003none ahead
Soligenixits history only30 open or runningphase 3since Jun 19, 2009Jun 19, 2009none ahead
Adamis Pharmaceuticalsits history only20 open or runningphase 3since Feb 6, 2019Feb 6, 2019none ahead
Enteron Pharmaceuticals10 open or runningphase 3since Oct 4, 2005Oct 4, 2005none ahead
Lunan Pharmaceutical Groupits history only11 open or runningphase 3since Jul 21, 2026Jul 21, 2026Jun 2028phase 3 · NCT07768891
SOFARits history only10 open or runningphase 1since Apr 26, 2021Apr 26, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Enteron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2005First study: phase 3 study in Graft vs Host DiseaseFirst studyNCT00233896 · 130 enrolled · United States

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Enteron Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00233896Graft vs Host Disease · United States3Completed130

How it is read

Names in the registry

  • “Beclomethasone dipropionate”, 6 entries
  • “Beclometasone/Formoterol/Glycopyrrolate”, 2 entries
  • “beclomethasone”, 2 entries
  • “beclomethasone dipropionate plus formoterol fumarate combination”, 2 entries
  • “Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.